Drug Profile
AC 430
Alternative Names: AC410/AC409; AC430Latest Information Update: 24 Dec 2013
Price :
$50
*
At a glance
- Originator Ambit Biosciences Corporation
- Class Anti-inflammatories; Antineoplastics; Small molecules
- Mechanism of Action Janus kinase-2 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Autoimmune disorders; Inflammation; Leukaemia
Most Recent Events
- 24 Dec 2013 Discontinued - Phase-I for Leukaemia in USA (PO)
- 24 Dec 2013 Discontinued - Preclinical for Autoimmune disorders in USA (PO)
- 24 Dec 2013 Discontinued - Preclinical for Inflammation in USA (PO)